(DXCM) DexCom - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 27.821m USD | Total Return: -17.7% in 12m
Avg Turnover: 380M
EPS Trend: 89.5%
Qual. Beats: 1
Rev. Trend: 98.6%
Qual. Beats: 1
Warnings
Choppy
Tailwinds
Confidence
DexCom, Inc. is a medical technology company specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes and metabolic health conditions. Its product portfolio includes the G6 and G7 integrated systems, the Stelo biosensor for non-insulin users, and remote monitoring applications like Dexcom Share. The company utilizes a direct marketing model targeting healthcare professionals, including endocrinologists and diabetes educators, to drive clinical adoption.
The CGM sector is characterized by high barriers to entry due to stringent regulatory requirements for Class II and Class III medical devices. DexCom operates within a recurring revenue framework, where the sale of disposable sensors provides a consistent income stream alongside the initial hardware purchase. Detailed performance metrics and valuation models are available on ValueRay for further analysis. Headquartered in San Diego, the company serves both domestic and international markets through a specialized distribution network.
- Stelo launch expands total addressable market to non-insulin using type 2 diabetics
- International expansion of Dexcom ONE+ drives sustainable long-term revenue growth
- Medicare coverage expansion for basal insulin users increases domestic patient volume
- Competitive pricing pressure from Abbott Laboratories impacts overall gross profit margins
- Regulatory approval timelines for next-generation biosensors influence investor sentiment and valuation
| Net Income: 930.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA 13.03 > 1.0 |
| NWC/Revenue: 43.75% < 20% (prev 36.56%; Δ 7.19% < -1%) |
| CFO/TA 0.27 > 3% & CFO 1.78b > Net Income 930.4m |
| Net Debt (-887.4m) to EBITDA (1.29b): -0.69 < 3 |
| Current Ratio: 1.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (393.6m) vs 12m ago -3.41% < -2% |
| Gross Margin: 61.84% > 18% (prev 0.59%; Δ 6.12k% > 0.5%) |
| Asset Turnover: 71.99% > 50% (prev 61.44%; Δ 10.55% > 0%) |
| Interest Coverage Ratio: 61.88 > 6 (EBITDA TTM 1.29b / Interest Expense TTM 16.7m) |
| A: 0.32 (Total Current Assets 4.33b - Total Current Liabilities 2.22b) / Total Assets 6.63b |
| B: 0.40 (Retained Earnings 2.63b / Total Assets 6.63b) |
| C: 0.15 (EBIT TTM 1.03b / Avg Total Assets 6.69b) |
| D: 0.75 (Book Value of Equity 2.74b / Total Liabilities 3.68b) |
| Altman-Z'' = 5.20 = AAA |
| DSRI: 0.81 (Receivables 1.11b/1.17b, Revenue 4.82b/4.15b) |
| GMI: 0.96 (GM 61.84% / 59.43%) |
| AQI: 0.88 (AQ_t 0.10 / AQ_t-1 0.11) |
| SGI: 1.16 (Revenue 4.82b / 4.15b) |
| TATA: -0.13 (NI 930.4m - CFO 1.78b) / TA 6.63b) |
| Beneish M = -3.30 (Cap -4..+1) = AA |
As of May 28, 2026, the stock is trading at USD 70.26 with a total of 5,858,770 shares traded.
Over the past week, the price has changed by +4.94%,
over one month by +14.41%,
over three months by -4.32% and
over the past year by -17.66%.
DexCom has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy DXCM.
- StrongBuy: 17
- Buy: 6
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 81.6 | 16.2% |
P/E Trailing = 30.9442
P/E Forward = 28.169
P/S = 5.7746
P/B = 9.4103
P/EG = 1.3445
Revenue TTM = 4.82b USD
EBIT TTM = 1.03b USD
EBITDA TTM = 1.29b USD
Long Term Debt = 1.24b USD (from longTermDebt, last quarter)
Short Term Debt = 20.5m USD (from shortTermDebt, last quarter)
Debt = 1.53b USD (from shortLongTermDebtTotal, last quarter) + Leases 143.0m
Net Debt = -887.4m USD (calculated: Debt 1.53b - CCE 2.42b)
Enterprise Value = 26.9b USD (27.8b + Debt 1.53b - CCE 2.42b)
Interest Coverage Ratio = 61.88 (Ebit TTM 1.03b / Interest Expense TTM 16.7m)
EV/FCF = 18.84x (Enterprise Value 26.9b / FCF TTM 1.43b)
FCF Yield = 5.31% (FCF TTM 1.43b / Enterprise Value 26.9b)
FCF Margin = 29.67% (FCF TTM 1.43b / Revenue TTM 4.82b)
Net Margin = 19.31% (Net Income TTM 930.4m / Revenue TTM 4.82b)
Gross Margin = 61.84% ((Revenue TTM 4.82b - Cost of Revenue TTM 1.84b) / Revenue TTM)
Gross Margin QoQ = 62.95% (prev 62.93%)
Tobins Q-Ratio = 4.06 (Enterprise Value 26.9b / Total Assets 6.63b)
Interest Expense / Debt = 1.09% (Interest Expense 16.7m / Debt 1.53b)
Taxrate = 25.97% (70.0m / 269.5m)
NOPAT = 765.0m (EBIT 1.03b * (1 - 25.97%))
Current Ratio = 1.95 (Total Current Assets 4.33b / Total Current Liabilities 2.22b)
Debt / Equity = 0.52 (Debt 1.53b / totalStockholderEquity, last quarter 2.96b)
Debt / EBITDA = -0.69 (Net Debt -887.4m / EBITDA 1.29b)
Debt / FCF = -0.62 (Net Debt -887.4m / FCF TTM 1.43b)
Total Stockholder Equity = 2.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.90% (Net Income 930.4m / Total Assets 6.63b)
RoE = 33.83% (Net Income TTM 930.4m / Total Stockholder Equity 2.75b)
RoCE = 25.88% (EBIT 1.03b / Capital Employed (Equity 2.75b + L.T.Debt 1.24b))
RoIC = 20.14% (NOPAT 765.0m / Invested Capital 3.80b)
WACC = 7.79% (E(27.8b)/V(29.3b) * Re(8.17%) + D(1.53b)/V(29.3b) * Rd(1.09%) * (1-Tc(0.26)))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -68.89 | Cagr: -2.42%
[DCF] Terminal Value 77.97% ; FCFF base≈1.09b ; Y1≈1.25b ; Y5≈1.84b
[DCF] Fair Price = 73.87 (EV 27.6b - Net Debt -887.4m = Equity 28.5b / Shares 385.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 89.51 | EPS CAGR: 20.39% | SUE: 2.66 | # QB: 1
Revenue Correlation: 98.61 | Revenue CAGR: 14.50% | SUE: 0.85 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.61 | Chg30d=+0.63% | Revisions=+33% | Analysts=20
EPS next Quarter (2026-09-30): EPS=0.67 | Chg30d=-0.61% | Revisions=+11% | Analysts=20
EPS current Year (2026-12-31): EPS=2.59 | Chg30d=+3.61% | Revisions=+77% | GrowthEPS=+23.7% | GrowthRev=+12.1%
EPS next Year (2027-12-31): EPS=3.05 | Chg30d=+1.82% | Revisions=+38% | GrowthEPS=+18.0% | GrowthRev=+11.5%
[Analyst] Revisions Ratio: +77%